Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech Entrepreneur Aldag Inspired By Italy's Genespire

New Chairman of Milan-Based Gene Therapy Firm

Executive Summary

Jörn Aldag, who has over 20 years of leadership experience in the life sciences industry, including CEO of gene therapy pioneer uniQure, tells Scrip that the research carried at the world-class Italian research institute SR-Tiget.

You may also be interested in...



Merck KGaA Rebounds After COVID-19 Lockdowns

The coronavirus pandemic hurt the German group's healthcare division but helped the contract development and manufacturing activities of Merck's life sciences business.

Roche Pharma Chief Picks Out Pearls in Cancer Pipeline

Oncology is an area where the Swiss major has long been a dominant player, and Bill Anderson highlighted programs to Scrip which Roche hopes will help extend that dominance.

Roche To Reinvest Savings Into R&D And Keep Prices Low

The Swiss major's pharma chief Bill Anderson tells Scrip that the goal for the firm over the next decade is to deliver twice as many medicines at a much lower cost to society.

Topics

Related Companies

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel